Sustained effects on immune cell subsets and autoreactivity in multiple sclerosis patients treated with oral cladribine.

"Conflict of interest RH has received speaker honoraria from Merck KGaA. MV has received speaker honoraria from Merck KGaA. MR has received support for congress participation from Merck KGaA. FS has served on scientific advisory boards for, served as consultant for, received support for congress participation or received speaker honoraria from Alexion, Biogen, Bristol Myers Squibb, Merck KGaA, Novartis, Roche and Sanofi Genzyme. His laboratory has received research support from Biogen, Merck KGaA, Novartis, Roche and Sanofi Genzyme. The remaining author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest."

"The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This study was financially supported by Merck A/S, Søborg, Denmark, an affiliate of Merck KGaA Darmstadt, Germany (CrossRef Funder ID: 10.13039/100009945), however Merck KGaA had no influence on the conduct, analysis, or interpretation of data. FS holds a professorship funded by the Danish Multiple Sclerosis Society."